Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2015 07:30 ET | Source: Melinta Therapeutics

Melinta Therapeutics Joins White House Forum on Antibiotic Stewardship in Commitment to Take Steps to Avert Potential Crisis

New Haven, CT, June 2, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics announced today it is joining with more than 150 other major food companies, retailers, and human and animal health stakeholders at...
January 07, 2015 13:40 ET | Source: Melinta Therapeutics

Melinta Therapeutics' Lead Candidate Delafloxacin Yields Positive Top-Line Results in Phase 3 Study in Patients with ABSSSI

New Haven, Conn, Jan. 7, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced positive top-line results from the first of two Phase 3 PROCEED studies (study RX-3341-302, NCT01811732) to...
August 14, 2014 10:38 ET | Source: Scienta Communications

Melinta Therapeutics Bolsters Board of Directors with Appointment of Christopher Kiritsy

NEW HAVEN, Conn, Aug. 14, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced the appointment of Christopher Kiritsy to the Company's Board of Directors. Mr. Kiritsy is currently president,...
August 11, 2014 12:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics Reports Top-Line Results Showing Equivalent Exposures after Oral and Intravenous Delafloxacin Administration

NEW HAVEN, Conn, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced top-line results of a Phase 1 clinical study that demonstrated that the administration of single doses of...
July 24, 2014 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics Announces Accepted Abstracts at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

NEW HAVEN, Conn, July 24, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that the company and investigators will be making eight presentations at the annual Interscience Conference...
June 17, 2014 14:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics to Present at Annual JMP Securities Healthcare Conference

NEW HAVEN, Conn, June 17, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that CEO Mary Szela will be presenting at the annual JMP Securities Healthcare Conference in New York, NY....
May 05, 2014 11:27 ET | Source: Melinta Therapeutics

Melinta Therapeutics' Phase 3 Study of I.V. and Oral Delafloxacin has Begun Enrolling Patients with Acute Bacterial Skin and Skin Structure Infections

NEW HAVEN, Conn, May 5, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that patient enrollment has commenced in a Phase 3 trial of oral and intravenous (I.V.) delafloxacin, a...
April 03, 2014 14:38 ET | Source: Melinta Therapeutics

Melinta Therapeutics to Present at Needham & Company's Annual Healthcare Conference

NEW HAVEN, Conn, April 3, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that Mary Szela, the Company's chief executive officer, will be presenting a corporate update at Needham...
November 19, 2013 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics Prepares for Late-Stage Product Launches with Appointment of Sue Cammarata, M.D. as Chief Medical Officer

NEW HAVEN, Conn, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced the appointment of Sue Cammarata, M.D. as chief medical officer. In this role, Dr. Cammarata will be...
October 07, 2013 09:51 ET | Source: Melinta Therapeutics

Melinta Therapeutics Announces Strategic Realignment and New Corporate Identity Based on Strong Scientific Foundation of Rib-X Pharmaceuticals

NEW HAVEN, Conn. & NEW YORK, Oct. 7, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc., formerly Rib-X Pharmaceuticals, today announced the launch a new corporate identity, an...